30 Day Trial

AxioMed Opens $10MM Funding Round


Following closure of an oversubscribed first round, AxioMed opened a US $10MM round of funding to support operations and ex-U.S. sales.

In 1Q17, the company completed collection and analysis of 2-year follow-up data in its U.S. Investigational Device Exemption (IDE) clinical study of its viscoelastic lumbar disc. AxioMed expects 1Q18 CE Mark approval for its lateral disc, and is pursuing a multi-level cervical IDE in the U.S. 

Sources: AxioMed; ORTHOWORLD Inc.